Moracizine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Moracizine (INN,[1] or moricizine, trade name Ethmozine) is an antiarrhythmic of class IC.[2] It was used for the prophylaxis and treatment of serious and life-threatening ventricular arrhythmias,[3] but was withdrawn in 2007 for commercial reasons.[4]
Pharmacology
Pharmacology
Moracizine, a phenothiazine derivative, undergoes extensive first-pass metabolism and is also extensively metabolized after it has entered the circulation. It may have pharmacologically active metabolites. A clinical study has shown that moracizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations. Compared with disopyramide and quinidine, moracizine was equally or more effective in suppressing premature ventricular contractions, couplets, and nonsustained ventricular tachycardia.
In the Cardiac Arrhythmia Suppression Trial (CAST), a large study testing the influence of antiarrhythmics on mortality, showed a non-significant increase of mortality from 5.4 to 7.2% under moracizine. This is in line with other class IC antiarrhythmics.[5]
References
References
- ↑ “The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances” (PDF). World Health Organization. 2009. p. 103.
- ↑ PMID 12402511 (PMID 12402511)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ British National Formulary (59th ed.). British Medical Journal Publishing Group, Pharmaceutical Press. 2010.
- ↑ “Shire Announces Ethmozine will be Available until December 31, 2007”. Heart Rhythm Society.
- ↑ PMID 1377359 (PMID 1377359)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH